DNM1 and cancer: The MiTMAB dynamin inhibitors share many favourable characteristics with inhibitors of Aurora kinases, Plk and KSP: (i) they do not affect any other phase of the cell division cycle and (ii) possess anti-proliferative and cytotoxic properties that are selective for cancer cells [4].